Serial analysis of hepatitis B virus core nucleotide sequence of patients with acute exacerbation during chronic infection

✍ Scribed by Okumura, Akihiko; Takayanagi, Masahiro; Aiyama, Toshiyuki; Iwata, Kazuo; Wakita, Takaji; Ishikawa, Tetsuya; Yoshioka, Kentaro; Kakumu, Shinichi

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 901 KB
• Volume: 49
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/(sici)1096-9071(199606)49:2<103::aid-jmv6>3.0.co;2-9

✦ Synopsis

Recent studies suggest that hepatitis B virus (HBV) core region could be an immunological target and that amino acid (aa) substitutions are mostly restricted to a small segment located in the middle of the core region. We sequenced the middle portion of HBV core gene during the course of acute exacerbation of chronic hepatitis B, and compared aa variations between the region including ideal HLA-A2 binding motifs and the nonbinding region. Five HBeAg+ chronic hepatitis patients with subtype adr (three with HLA-A2 and two without HLA-A2) were selected and using polymerase chain reaction (PCR) and cloning system, the central part of core region (nt 2063 to 2365,303 bp) was sequenced in sera from each patient at three time points; before, at the peak of, and after exacerbation of hepatitis. The second set of sera showed higher aa substitution rates in five and in three out of five patients compared with those of the first and third sera, respectively. No significant difference was found in the aa substitution rates for the region with ideal HLA-A2 binding motifs between patients with and without HLA-A2. In asymptomatic HBV carriers with persistently normal aminotransferase values, alterations of the aa sequence were not observed within the same time frame. The results suggest that aa substitutions often occur at some particular positions in the middle of HBV core region during acute exacerbation of the disease under possible host immune pressures. Furthermore, unidentified epitopes appear to exist in the central part of HBV core region and HLAunrestricted lymphocytes may play a role in the immune response of chronic HBV carriers.